Reading INDV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDV free→Reading INDV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDV free→QuarterlyIQ Insights · INDV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Scientific Officer — Dr. Christian Heidbreder: The position of Chief Scientific Officer is being eliminated and Dr. Heidbreder's employment will terminate.
Other. On May 4, 2026 the Company issued a press release announcing that it had entered into an accelerated share repurchase agreement (the “ASR Agreement”) with an investment bank counterparty (the “Counterparty Bank”) to repurchase $175.0 million (the “Prepayment Amount”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), as part of the Company’s previously announced $400 million share repurchase program (the “Share Repurchase Program”). The full text…
Results of Operations and Financial Condition. On April 30, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended March 31, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.